From Citrus Fruit to

Medical Breakthrough:
The unique history and future of
Modified Citrus Pectin

A Better Health Publishing® Wellness Guide

Santa Rosa, CA
 Foreword By:
Dr. Isaac Eliaz
“One day, they will find out that there is a cure for
cancer in the peel of an orange.”

I’ll never forget these words. They came from Dr. Ruth Cohen,
a neighbor of mine during my childhood in Israel 40 years
ago. In a country known for its prized citrus fruits, she and
her husband, Leo, were organic chemistry scientists with a
particular focus on the study of citrus pectin.

Decades later, after becoming a doctor with a specialty in

Integrative Cancer Treatments, I began to see how true Ruth’s
statement really was. What once seemed like mere wishful
thinking had become a remarkable reality. In fact, a large body
of scientific research now shows that a substance from the
pith of citrus fruits, known as Modified Citrus Pectin (MCP),
may well be one of the most important natural compounds to
emerge in the last 20 years.

Today, there is a vast body of MCP research for cancer

fighting properties and significant benefits for serious chronic
conditions. My life’s mission is to research and develop natural
solutions that can fight disease and restore health, which is why
I am excited about these discoveries that offer exciting new
hope for everyone seeking safe and effective natural solutions.

In best health,

Isaac Eliaz, M.D., M.S., L.Ac.

Medical Director, Amitabha Medical Clinic
 C h ap t e r
1

The Importance of Modified Citrus Pectin

MCP Effectively Fights Cancer and More…

Many years of scientific and clinical research demonstrate

that Modified Citrus Pectin (MCP) is a powerful and natural
cancer fighter. Once known solely for this benefit, newer
studies have established its value for inflammatory and fibrosis
related conditions like cardiovascular disease, kidney disease,
liver cirrhosis, diabetes and arthritis. This is because MCP is a
natural blocker of Galectin-3.

In the last few decades, hundreds of studies have proven

that Galectin-3 plays a role in cancer development. In small
amounts, galectins are perfectly healthy and actually aid
cellular communication, and healthy growth and development.
However, studies show that excess Galectin-3 in the body
directly promotes unhealthy cell behaviors such as inflammation,
uncontrolled abnormal cell growth, colony formation (tumors),
and metastasis, among others.

Because MCP is small enough to enter the bloodstream, and is

naturally attracted to Galectin-3, it will bind and block over-
From Citrus Fruit to Medical Breakthrough

expressed Galectin-3 molecules present in the body. This is the

main mechanism by which MCP can prevent the growth and
spread of cancer and other chronic degenerative conditions.
In fact, Modified Citrus Pectin is the only natural substance
proven to block excess Galectin-3 molecules in the body and
prevent them from promoting cancer and other deadly diseases.

Other Unique MCP Benefits

In addition to addressing a number of specific health conditions,

several clinical studies show that Modified Citrus Pectin can
safely remove harmful heavy metals, radioactive isotopes and
environmental toxins from the body. MCP’s unique molecular
structure makes it easily absorbed into the blood stream where
it can safely and gently remove health robbing toxins, without
affecting essential mineral levels.

MCP has also been shown to activate the lymphocyte cells

known as Natural Killer (NK) cells in human blood samples.
NK cell activity has been demonstrated to destroy leukemia
cells in culture.
 C h ap t e r
2

The Science & Development of MCP

The Critical Difference between Regular Pectin and

Modified Citrus Pectin

We encounter unmodified pectin on a regular basis as a

thickening agent for jams, jellies and other foods, yet the
medical benefits of pectin are not widely recognized. On a basic
chemistry level, pectin is a soluble fiber found in abundance in
the peels of fruits like oranges, lemons, grapefruits and apples.
Besides its usefulness in our diet, pectin actually provides a
number of health benefits, especially in the digestive tract where
it can help to remove toxins from the intestines and colon.

In the intestinal tract, pectin can bind and help remove mutagens
which have harmful particles such as heavy metals, radioactive
isotopes, and environmental toxins capable of mutating DNA,
disrupting cellular functions, and wreaking havoc in the
body. This is why pectin is known to reduce cancerous risks
to your colon, and there are over a dozen published studies
demonstrating this relationship.

While the benefits of pectin to the digestive tract were

From Citrus Fruit to Medical Breakthrough

understood for many years, its molecules are simply too large
to provide benefits to other parts of the body. The additional
disease-fighting properties in pectin remained untapped until
the discovery of Modified Citrus Pectin.

First Scientific Validation of MCP

In the ongoing search for a safe, natural substance useful in

cancer therapy, Modified Citrus Pectin has emerged as one
of the most promising. The first research on Modified Citrus
Pectin was published in 1992 by Dr. Avraham Raz, a researcher
at Wayne State University. Knowing the benefits of regular
pectin, Dr. Raz was able to successfully demonstrate that a
smaller pectin molecule could provide benefits in the fight
against cancer.

Understanding the vital importance of these findings, a handful

of doctors and researchers developed and standardized Modified
Citrus Pectin — a natural pectin powder that is molecularly
much smaller than regular pectin. With a smaller size, MCP’s
molecules can be easily absorbed into the bloodstream for
maximum distribution throughout the body. Through this
novel and safe modification, a flood of previously unknown
health applications emerged, heralding a new chapter in the
field of integrative cancer research.
 C h ap t e r
3

Modification Creates a Powerful Substance

Discussing the molecular composition of any substance can

make for a complex topic. But since it is crucial to MCP’s
benefits, let’s further explore the differences between regular
pectin and Modified Citrus Pectin, and discuss the correct
standards for an effective MCP.

The Importance of Molecular Weight and

Esterification

The size of pectin molecules ultimately determine where they

can go and what they can do, and this value is expressed in
terms of molecular weight, or kilodaltons (kDa). Regular pectin
molecules are between 50 and 300 kilodaltons (kDa); far too
large to enter the bloodstream and offer whole body health
benefits.

To create an effective Modified Citrus Pectin, the proper

method employs an enzymatic and pH process to yield an
average molecular weight range between 3 and 15 kDa. This
is the most scientifically proven and biologically active weight
and the only MCP size that has been shown to be effective in
From Citrus Fruit to Medical Breakthrough

human clinical trials.

Along with the correct molecular weight, another key factor

to consider is the pectin’s degree of esterification — and the
rule of thumb is the smaller, the better. Regular pectin has a
degree of esterification of about 70 percent — but even some
modified forms have as much as 50 percent, rendering it largely
ineffective. The most powerful preparations of Modified Citrus
Pectin have a degree of esterification of less than 10 percent. If
the degree of esterification is too high, then the pectin chains
link together and cross-bridge to each other, instead of blocking
the harmful effects of Galectin-3.

When looking for the most effective MCP, the molecular

weight needs to be between 3 and 15 kDa and the esterification
should be below 10 percent.

MCP

MCP binds to galectin-3

preventing cell interactions
Free Cancer Cells

Cancer cell death

 C h ap t e r
4

The Only Proven Natural

Galectin-3 Inhibitor
How Galectin-3 Promotes Cancer

It’s important to understand how cancerous cell behavior differs

from normal, healthy cell behavior, so let’s take a moment to
explain some of the biological misfires involved in cancer’s
formation.

Healthy cells die and regenerate as part of an orderly cell cycle

— as one dies, another is produced to replace it. When this cell
cycle is disrupted, it causes cells to “pile up” and form a tumor.
As long as these cells appear normal and static, the tumor is
considered harmless or “benign.”

Unlike benign tumors, cancerous tumors are malignant.

They’re marked by uncontrolled growth and the ability to
spread aggressively, a process known as metastasis. Given the
opportunity, they will spread through your entire body, invading
healthy tissues and causing new tumors. And this dangerous
ability hinges on the presence of excess Galectin-3.
From Citrus Fruit to Medical Breakthrough

Galectin-3 promotes cancer progression in 3 interconnected

ways:

1. It allows cancer cells to attach to one another, forming groups

that can survive in your bloodstream and migrate to other parts
of your body.
2. Once cancer cells have formed a primary tumor, Galectin-3
allows the cells to aggregate and grow, and attach themselves
to new sites as well, forming secondary tumors.
3. Galectin-3 nourishes malignant tumors by stimulating new
blood vessel growth (even where there was no blood supply
before) to feed the tumor. This process is called angiogenesis.

It’s no surprise then that Galectin-3 molecules have become a

therapeutic target in modern cancer prevention and treatment.
If you disarm a cancer cell’s ability to attach and communicate,
you essentially pull the plug on its power supply. If it cannot
spread or nourish itself, ultimately it will not survive or
proliferate.

Modified Citrus Pectin’s affinity to bind to Galectin-3 makes it

a vital weapon in blocking the spread of cancer. By attaching to
and blocking Galectin-3 on cancer cells’ surface, it can disable
their ability to communicate, nourish themselves and grow.

Galectin-3

Cancer cells form

tumors by binding via
Free Cancer Cells
galectin-3 molecules
 C h ap t e r
5

MCP and Prostate Cancer

Many men have benefited from the use of Modified Citrus

Pectin before, during, and after a diagnosis of prostate cancer.
As we’ll discuss here, the body of MCP research for prostate
cancer is quite impressive.

Dramatic Scientific Findings

In 1995, the first in vivo research on prostate cancer metastasis

was conducted by Dr. Kenneth J. Pienta. The results were
excellent, showing a 56 percent decrease in lung metastasis —
a significant difference. This important study was published
in the prestigious Journal of National Cancer Institute ( JNCI).
Dr. Pienta’s results paved the way for future MCP research,
and the first human trial — a pilot study conducted by Dr.
Isaac Eliaz along with Dr. Stephen Strum in 1995 and 1996
— was presented at the International Conference on Diet and
Prevention of Cancer in Finland in 1999.

In this pilot study, seven patients, with local recurrence of

prostate cancer after local therapy, were administered 15 grams
of MCP in three divided daily doses for 12 full months (15 grams
From Citrus Fruit to Medical Breakthrough

daily is the standard recommended dose for cancer patients).

During the study, PSA doubling time, a measurement that
reflects the rate at which the cancer is growing, was evaluated
at the three, six and twelve month mark and the results were
extremely promising: four out of seven patients responded with
a lengthened prostate specific antigen doubling time (PSADT)
of more than 30 percent. Of the others, one patient was judged
to have a partial response, one was judged to have stable disease,
and the remaining judged as having no response. Lengthening
of the PSADT reflects a slowing down in the progression of
the cancer.

Additional analysis using prostate cancer cells was also presented

at the conference in Finland, revealing that MCP does indeed
interfere with cancer cell growth and metastasis, resulting in
cytotoxicity (cancer cell death) of 80.7 percent, compared with
only 3.8 percent in the control.

Further Exploration and Results

Both of these studies warranted a longer and more controlled

phase-II clinical study, which was completed in December
2003. This time 10 patients with biochemical relapse of
prostate cancer after local therapy were given 15 grams in
three daily doses of MCP each day for a year. 70 percent of the
participants showed positive response to this treatment, with
a significant slowing in the rise of their PSA. In fact, six out
of ten patients more than doubled their PSA doubling time —
ultimately leading to a significant reduction in the chance of
dying prematurely.
Columbia University: MCP Effective for Aggressive
Prostate Cancer

In 2010, research from Columbia University was published

in the journal Integrative Cancer Therapies offering additional
answers as to how Modified Citrus Pectin achieves its
remarkable anti-cancer effects. Laboratory results indicated
that MCP can inhibit cell proliferation and promote apoptosis
(programmed cell death) in prostate cancer cell lines (including
androgen-dependent and androgen-independent cells). It was
also shown to inhibit cell proliferation by reducing a cellular
signaling process used by cancer to spread and proliferate
throughout the body. This process is called mitogen-activated
protein (MAP) kinase signaling.

The ability to induce apoptosis in androgen-independent

prostate cancer cell lines is especially significant, as this is
the more aggressive form of prostate cancer that can become
resistant to treatment, metastasize, and lead to premature
death. Any help in slowing down the progression of this cancer
obviously has a direct effect on prolonging a patient’s life.

In closing, it must be said that even with all these significant

benefits, Modified Citrus Pectin as a stand alone isn’t a cure
for prostate cancer. But it is extremely valuable for any man in
“watchful waiting” or “active surveillance” and a very important
adjunct to standard treatment — not least of all because of the
many unique benefits that continue to emerge with ongoing
research into MCP use.
 C h ap t e r
6

MCP Fights Breast Cancer and More

With the diagnosis of breast cancer at all time highs, the

necessity of natural solutions is paramount. Fortunately, like
prostate cancer in men, Modified Citrus Pectin also has very
important benefits for women.

In a 2002 in vivo breast cancer study, published in the Journal

of the National Cancer Institute, Modified Citrus Pectin’s
effects on breast tumors were studied using varying doses.
Results showed that MCP treatment inhibited tumor growth,
angiogenesis and metastasis in mice (with larger doses yielding
stronger results) via the blocking of Galectin-3. Earlier in vitro
research supported these results revealing the same reduced
angiogenesis (creation of new blood vessels that feed tumors)
and cancer cell adhesion.

In addition to MCP’s role in preventing and treating breast and

prostate cancer, other MCP studies suggest that this versatile
substance plays a crucial role in protecting against skin cancer.
One study (published in the Journal of the National Cancer
Institute) showed that while regular pectin demonstrated no
positive effects on melanoma cells, the administration of MCP
From Citrus Fruit to Medical Breakthrough

remarkably reduced tumor metastasis by over 90 percent. These

incredible results were supported two years later in a follow-
up study that demonstrated a similar decrease in melanoma
progression. The study authors attributed this remarkable effect
to MCP’s superior Galectin-3 binding capabilities.

New Hope for Treatment Resistant Cancer

In 2008, a German study tracked a group of 49 patients with

multiple types of cancer: colon, breast, lung cancer, pancreatic,
ovarian, throat and others. These were not early-stage diagnoses.
These patients had advanced cancers, most of which had
metastasized. They had unsuccessfully gone through surgery,
radiation therapy and chemotherapy.

And yet, 5 grams of Modified Citrus Pectin 3 times per day

improved the quality of life and reduced pain in the majority (53
percent) of these patients. In fact, one patient with advanced
prostate cancer had a 50 percent decrease in his PSA level over
the period of 16 weeks, with an equally significant decrease in
his clinical symptoms and his pain. This incredibly promising,
especially for anyone who has been failed by available treatments.

Furthermore, the results of this study are equivalent to and in

some cases better than the chemotherapy results achieved in the
same group of patients — and without the toxicity and side
effects. While, MCP is not a replacement for conventional
therapy, it is an integral part of a comprehensive program for
cancer patients. It also quite possibly offers a new lease on life
for anyone with advanced stage, treatment-resistant tumors.

Combined Synergy: MCP Benefits Conventional

Chemotherapy and other Treatments

Integrative medicine demonstrates that the battle against

cancer is best won by attacking it from multiple angles using
synergistic anti-cancer therapies and treatments. Synergistic
action means that different therapies work together and
enhance each others beneficial effects. Here’s a simple metaphor
to explain synergistic action: with synergy, 1 + 1 equals not just
2, but 3, or 5, or even 100, depending on which treatments are
being used together. The strategic synergistic combination of
various therapies is one of the keys to successful integrative
health treatment.

Clinical observations show that MCP has the power to enhance

chemotherapy, and can also help the body to deal with some
of chemotherapy’s harmful side effects, which often further
destroy a person’s health. By using Modified Citrus Pectin
in conjunction with traditional chemotherapy, a patient may
receive the benefits of a synergistic action against the cancer.
This synergy may allow for a lower dose of chemotherapy,
less side effects, and a greater clinical outcome. A synergistic
anti-cancer effect has also been seen when MCP is used in
conjunction with specialized botanical formulas, to fight cancer
and prevent metastasis via multiple mechanisms of action.
From Citrus Fruit to Medical Breakthrough

MCP is Critical Before and After Surgery/Biopsy

Cancer surgery or diagnostic biopsy is sometimes a necessary

choice. If this is the case, MCP is a critical ally which can
help protect against further damage potentially caused by
these procedures. While cancer surgeries and biopsies may be
necessary, they are not risk free. These procedures can create
inflammation and damage to the surrounding tissue and
circulation, increasing the potential for further growth and
spread of the cancer. The injury to the tissue can increase
inflammation and cause increases in various growth factors
such as VEGF and EGF, both promoters of cancer growth.
Surgery and biopsy can also increase the aggressive behavior of
cancer cells, release them to migrate from the primary tumor
site and invade other tissues, promoting metastasis.

That’s where MCP can play a critical role in protecting against

cancer proliferation, invasiveness and metastasis after surgery
or biopsy. By taking 5 grams three a times a day for two weeks
prior, and two to four weeks after the procedure, patients can
also reduce inflammation and abnormal scar tissue by relying
on MCP’s ability to bind and block Galectin-3. Some patients
increase the dosage in the 24 hours before the procedure to 20-
25 grams. Supplying an active dose of MCP before and after
will help to protect against aggressive cancer cell behavior and
potential metastasis following such a procedure.
 C h ap t e r
7

MCP Removes Heavy Metals

and Radiation
Safely Chelate Toxic Metals and Radioactive Isotopes
From Your Body for Improved Health

Another essential benefit of Modified Citrus Pectin is that

it safely and gently chelates (tightly binds & removes) heavy
metals and toxins from the body.

Heavy metals and toxins are a silent but serious health threat.
Regrettably, we encounter toxins on a daily basis: there’s
mercury in amalgam dental fillings and in fish and seafood; lead
in foods, old paint and water pipes; and numerous other heavy
metals present in our air, water, soil and food chain. Even with
the best efforts, it’s nearly impossible to avoid some level of
exposure, and even small amounts can accumulate in our body
and contribute to the development of serious chronic illnesses.

Heavy metal toxicity can be seen in everything from chronic

pain and high blood pressure to a variety of neuro-degenerative
conditions and, most notably, cancer. Heavy metals distort
cellular communication signals, mutate DNA, impair the
immune system and disrupt numerous critical biological
From Citrus Fruit to Medical Breakthrough

functions. Even if your heavy metal intake is limited to miniscule

amounts at a time, these metals can build up gradually in bone
and soft tissue, leading to very serious conditions down the
road.

Given these harmful effects, the removal of toxic heavy metals

is essential in reducing health risks; which is why the discovery
of MCP’s chelating powers presented such an exciting
advancement in chelation and detoxification therapy. Once
again, it’s the unique molecular structure of MCP that provides
the ability to remove these toxins, without removing essential
minerals, as many other chelation agents unfortunately do.

MCP & the “Egg Box”

Modified Citrus Pectin belongs to a specific class of

polysaccharides known as polyuronides. Studies on polyuronides
demonstrate that they can remove heavy metals and toxins.

In solution, MCP’s negatively-

charged fiber chains stack together
to create pockets, forming what
we call an “egg box.” Heavy metals
have a strong positive charge and are
attracted to these fiber chains, which
cause the metal ions to bind to the
pockets. Over time this process can
stimulate a more thorough release of
heavy metals and toxins from deep
within your soft tissues where they’re
accumulating.
Once they come in contact with the “egg box,” heavy metals
become trapped and bound in the pockets, allowing them to be
safely excreted from your body.

Pectin First Used in Chernobyl

Reports of pectin’s remarkable effectiveness for toxin removal

first surfaced during the efforts to minimize the devastating
consequences of the Chernobyl disaster and radiation poisoning
among local residents. In a multitude of cases, pectin prevailed
as a powerful antidote to the toxic radiation by binding to the
radioactive particles in the digestive tract and safely removing
them. As the radiation fallout entered the food chains, children
who received a diet which included pectin had significantly
fewer cases of thyroid cancers than were occurring in the
regions not receiving a pectin-rich diet.

Intrigued by the years of research following this natural

approach to mitigating the effects of this overwhelming disaster,
Dr. Isaac Eliaz headed a pilot study in collaboration with the
United States Department of Agriculture (USDA) scientists
to study Modified Citrus Pectin’s ability to bind and remove
toxic heavy metals. Not only were the results impressive, but
they showed that MCP chelation does not disturb the body’s
essential mineral balance or cause any adverse side effects.

Clinical Studies on MCP and Heavy Metal Toxicity

Following the publication of this research with the USDA,

Dr. Eliaz published a multiple case study peer reviewed report
involving 5 patients from his clinic, Amitabha Medical Clinic
and Healing Center in Sebastopol, California. Using MCP,
From Citrus Fruit to Medical Breakthrough

it was the first study of its kind to show the relationship

between heavy metal removal and the subsequent reduction of
a wide range of clinical symptoms. In fact, not only did all five
patients decrease their heavy metals by an impressive average
of 74 percent, but participants’ clinical symptoms ranging
from elevating PSA levels to asthma, IBS, adrenal fatigue, and
depression, were significantly improved as heavy metal body
burden was reduced over time. No adverse effects were reported.
This affirming clinical evidence pointed to an important truth
— namely, that heavy metals are a very prominent and deadly
contributing factor in a wide range of serious health conditions.

In 2008, a study was published in the journal Alternative Therapies

in Health and Medicine, demonstrating the effectiveness of using
Modified Citrus Pectin as an antidote to acute lead poisoning
in hospitalized children in China. These children all came from
the same village where a battery producing plant was based.
Their poisoning resulted in detectable levels of lead in their
blood, and was enough to hospitalize them with symptoms.

The study followed their

treatment with 5 grams
of MCP 3 times a day
for several weeks, and
monitored their blood and
urine lead content levels.
They showed that their
blood lead content levels
decreased dramatically, and
that lead was being expelled
in their urine. All the
children in the study saw a
dramatic improvement and were able to be released from the
hospital within three weeks, without side effects. Thankfully,
the hospital involved in this study has reported that the battery
plant in this village has since been shut down.
 C h ap t e r
8

Heart Failure, Fibrosis,

Immune Health & More...
New Applications for MCP

As we discussed earlier, the understanding of MCP’s value

has grown significantly due to a number of key studies
demonstrating the role of Galectin-3 in the progression of
chronic diseases related to inflammation and fibrosis, including
heart disease. Fibrosis is responsible for many chronic and
deadly disease states, because of the uncontrolled inflammation
and subsequent overproduction of excessive scar tissue within
various organs and systems.

In a 2011 pre-clinical research study out of the United Kingdom,

scientists found that Modified Citrus Pectin interrupts deadly
kidney fibrosis by binding to Galectin-3 molecules, decreasing
the effects of inflammation and fibrosis in a kidney injury
model. These results demonstrated MCP to be an effective
agent in protection against inflammation and kidney fibrosis
injury.
From Citrus Fruit to Medical Breakthrough

Galectin-3’s Involvement in Chronic Diseases

Arthritis
The finding that Galectin-3 is present in the inflamed joints in
patients with rheumatoid arthritis strongly suggests that this
protein is associated with the development and progression
of this degenerative disease. Further research proves that
Galectin-3 plays a large role in the development and
progression of rheumatoid arthritis and that the disease severity
is accompanied by harmful immune responses influenced by
Galectin-3.

Diabetes
Diabetes resistance has also been linked to reduced Galectin-3.
Mice with reduced Galectin-3 levels were shown through
various measurements of diabetes progression to be resistant
to the development of diabetes, as compared with mice that
had normal levels of Galectin-3. The same mice with reduced
Galectin-3 levels also showed a reduction in inflammation.
Related research has demonstrated that reduction in Galectin-3
levels slows the breakdown of the inner blood-retinal barrier
that typically occurs early in diabetes.

Liver Fibrosis
Inflammation and fibrosis of the liver has also been linked to
excess Galectin-3.

Galectin-3’s Involvement in Cardiac Diseases

Cardiovascular Disease
Using MCP to reduce Galectin-3 levels offers an important
treatment option for cardiac diseases, particularly by reducing
cardiac inflammation and fibrosis. Reducing Galectin-3 levels
in the cardiac tissues of mice resulted in lowered inflammation
and fibrosis in the cardiovascular system. Further studies
suggest that lowering galactin-3 levels following a heart insult
or cardiac event can reduce or suppress cardiac fibrosis and
heart disease.

FDA Approved Blood Test Measures Circulating

Galectin-3 for Cardiovascular Disease

Some of the most important recent research on Galectin-3 has

demonstrated the link between high levels of Galectin-3 and
chronic heart failure, giving value to Galectin-3 as a biomarker
of inflammation and fibrosis in patients with progressive
heart disease. In 2010, the FDA approved a blood serum
Galectin-3 test that is now available and covered by most
medical insurances. This inexpensive tool helps to determine
cardiovascular risks and disease prognosis, and can also be used
to determine metastatic cancer risk and progression.

The Future of Galectin-3 Research

Due to new developments in Galectin-3 research, the

relationship between Galectin-3 and many chronic health
conditions are now highly documented. Galectin-3 research
continues in other areas as well, such as gastrointestinal
conditions, allergies and hypersensitivities, skin conditions,
parasitic diseases, lung diseases (including asthma), and
immune conditions including auto-immune diseases.
From Citrus Fruit to Medical Breakthrough

Galectin-3 Reference Ranges

This chart explains Galectin-3 test results which are measured

as nanogram/millileter (ng/ml).

Extreme Risk: High Risk: Ideal Levels:

>17.8 14.0 to 17.8 <14.0 to 12.0
Indicates high risk General Population
for cancer, heart <14.0 ng/ml
failure, and fibrosis in Indicates significant
general populations. increased risks for
cancer, congestive Cancer Patients:
For congestive heart heart failure, fibrosis, <12.0 ng/ml
failure patients, these and overall mortality.
levels indicate extreme Congestive Heart
risk of adverse cardiac Failure Patients:
event. <12.0 ng/ml

- Galectin-3 levels above 17.8 ng/ml are considered to be an extreme risk factor of mortality.
- Ideal levels are below 14 ng/ml in the general population.
- For cancer and cardiac patients, ideal levels are below 12 ng/ml.
- It’s important to recognize that when levels change by 20% within 3 months, these changes correlate
with increases or decreases in disease progression and mortality risk.

Circulating Galectin-3 as a Biomarker of

Metastatic Cancer

Increased concentrations of free circulating Galectin-3 are

commonly seen in the blood of many types of cancer patients
including prostate, thyroid, gastric and colorectal cancer
patients. Recent studies have shown that increases in circulating
Galectin-3 levels in cancer patients contribute significantly to
the metastatic spread of their cancer.

Increases in Galectin-3 levels enhance the cancer’s ability to

adhere to blood vessel walls and also avoid immune surveillance
and detection. Results suggest that the interaction between free
circulating Galectin-3 and cancer-associated “transmembrane
mucin protein” (MUC1), promotes cancer cell clustering and
the survival of tumor cells circulating in the body. By targeting
and interrupting the interaction of circulating Galectin-3
with MUC1 proteins, Modified Citrus Pectin offers another
effective mechanism of action for preventing cancer metastasis.

MCP Demonstrates Powerful Immune Activation

Properties

Another unique function of MCP was demonstrated in a 2011

study, showing its immune activation properties. Studies using
human blood samples showed that MCP activated T-cytotoxic,
B and Natural Killer (NK) immune cells in a leukemia model. NK
cells play a major role in the rejection of tumors and cells infected
by viruses. NK cells that were activated by MCP demonstrated
increased functional ability in inducing cancer cell death among
chronic myeloma leukemia cells. This research has paved the
way for further investigation into these immune enhancement
properties, and has also given science a more comprehensive
understanding of MCP’s potent cancer fighting properties.

MCP supports appropriate immune response including

powerful NK cell activation and increased functionality,
essentially “tagging” the cancer cells for immune cell attack.
 C h ap t e r
9

The Future of MCP

Ongoing validation of Modified Citrus Pectin’s multiple health

applications is helping integrative health care treatments world-
wide. Thanks to the work of dedicated scientists, researchers,
and integrative doctors, the medical community and those
interested in achieving and maintaining natural health
will benefit from MCP in the treatment of a wide range of
conditions. As research on this important substance continues,
and as more health professionals and patients seek out effective
natural solutions, Modified Citrus Pectin will surely be known
as a very valuable substance involved in the maintenance of
long term health and longevity.

As the only scientifically proven natural Galectin-3 blocker,

Modified Citrus Pectin is important in the prevention and
treatment of cancer, inflammation, cardiovascular disease and
fibrosis, as well as being a valuable substance in the treatment
of heavy metal toxicity, immune function and more. Thus,
anyone concerned about the prevention, development and
management of these conditions should consult your doctor
about testing your levels of Galectin-3, along with heavy metal
body burden, and to add daily MCP supplementation to your
From Citrus Fruit to Medical Breakthrough

diet as an effective tool in preventing disease and maintaining

long term health.

As promising new research on MCP’s role in health and disease

continues to emerge from the scientific community, future
editions of this important body of knowledge will be updated
to share with anyone seeking safe and effective natural health
solutions.
 App endi x
i

How to use MCP

MCP Dosage Per Day

Galectin-3 No Known Cardiovascular Active Cancer Post Cancer
Test Results Medical Inflammation (3 years)
Conditions Fibrosis
Hepatitis
< 12 ng/ml 5 grams 5 grams 15 grams 5 grams
12-14 ng/ml 5 grams 10 grams 15 grams 10 grams
14-17.8 ng/ml 10 grams 15 grams 15 grams 15 grams
> 17.8ng/ml 15 grams 15 grams 20-25 grams 20-25 grams
Not Tested 5 grams 15 grams 15 grams 15 grams

MCP Dosage per Day for Heavy Metal Toxicity

Elevated levels Frequent Low levels of Normal exposure Cleansing and
of heavy metals exposure to heavy metals to heavy metals, detoxification
(hair or urine heavy metals (hair or urine or for prevention
analysis) analysis)
15 grams 15 grams 5 grams 5 grams 15 grams for 3-6
months
From Citrus Fruit to Medical Breakthrough

Frequently Asked Questions

What is the most effective way to dissolve Modified Citrus
Pectin powder into liquid?
1. Put one 5 gram scoop of Modified Citrus Pectin into a glass.
2. Add your liquid (water, juice, or tea). DO NOT STIR YET.
3. Let sit 3-5 minutes to allow the powder to rehydrate.
4. Stir contents until powder is dissolved.

What is the best liquid to mix Modified Citrus Pectin powder

with?
Water is best, but some people do use other liquids, such as juice.
Modified Citrus Pectin has a very mild, bland taste.

What citrus fruits are used to make Modified Citrus Pectin?

The pectin contained in Modified Citrus Pectin is derived from
lemons, limes, oranges and grapefruit. It is made from the pith of
the fruit, no juice, pulp or any part of the “fruit” is used. Modified
Citrus Pectin does not cause a “grapefruit” effect on absorption of
medications.

What is the best way to store Modified Citrus Pectin?

Modified Citrus Pectin can be stored in ambient (room temperature)
conditions, it is not necessary to store it in the refrigerator. Modified
Citrus Pectin is a very stable material, and can withstand extreme
temperatures.

Does Modified Citrus Pectin contain Vitamin C?

No, Modified Citrus Pectin does not contain any Vitamin C.

Is it okay to give Modified Citrus Pectin to my dog or cat?

Yes. Average, mid-sized dogs may take 1 scoop daily. Cats should
take only ½ scoop, as they are smaller. It is usually best to mix it with
your pets’ fresh daily water.
From Citrus Fruit to Medical Breakthrough

Forsman H, Islander U, Andréasson E, Andersson A, Onnheim K, Karlström A, Sävman K, Magnusson M, Brown KL, Karlsson A.
Galectin 3 aggravates joint inflammation and destruction in antigen-induced arthritis. Arthritis Rheum. 2011 Feb;63(2):445-54.

Guess B, Scholz M, Strum S, Lam RY, Johnson HJ, Jennrich RI. Modified citrus pectin (MCP) increases the prostate specific antigen
doubling time in men with prostate cancer: A Phase II clinical trial. Prostate Cancer Prostatic Dis. 2003;6(4):301-4.

Gunning, P, Bongaerts, RJM, Morris, VJ. Recognition of galactan components of pectin by Galectin-3. FASEB J. 2009, 23, 415–424.

Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, Liu FT, Hughes J, Sethi T. Galectin-3 expression and
secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008 Feb;172(2):288-98.

Hexeberg S, Hexeberg E, Willumsen N, Berge RK. A study on lipid metabolism in the heart and liver of cholesterol- and pectin-fed
rats. Br J Nutr, 1994, Feb, 71(2):181-92.

Honjo Y, Nangia-Makker P, Inohara H, Raz A. Down-regulation of Galectin-3 suppresses tumorigenicity of human breast carcinoma
cells. Clin Cancer Res. 2001 Mar;7(3):661-8.

Hsu DK, Chen HY, Liu FT. Galectin-3 regulates T-cell functions. Immunol Rev. 2009 Jul;230(1):114-27.

Iacobini C, Menini S, Ricci C, Fantauzzi CB, Scipioni A, Salvi L, Cordone S, Delucchi F, Serino M, Federici M, Pricci F, Pugliese
G. Galectin-3 ablation protects mice from diet-induced NASH: A major scavenging role for Galectin-3 in liver. J Hepatol. 2011
May;54(5):975-83.

Inohara H, Raz A. Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to Galectin-3
functions. Glycoconj J, 1994; 11(6): 527-32.

Jiang, J, Isaac Eliaz, I, Sliva, D. Synergistic effect of modified citrus pectin with two novel poly botanical compounds, in the suppression
of invasive behavior of human breast and prostate cancer cells. 2011 (Submitted for Publication).

Johnson KD, Glinskii OV, Mossine VV, Turk JR, Mawhinney TP, Anthony DC, Henry CJ, Huxley VH, Glinsky GV, Pienta KJ, Raz A,
Glinsky VV. Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. Neoplasia. 2007 Aug;9(8):662-70.

Kolatsi-Joannou, M, Price, KL, Winyard, PJ, Long, DA. Modified citrus pectin reduces Galectin-3 expression and disease severity in
experimental acute kidney injury. PLoS ONE 6(4): e18683. doi:10.1371/journal.pone.0018683

Li W, Jian-jun W, Xue-Feng Z, Feng Z. CD133(+) human pulmonary adenocarcinoma cells induce apoptosis of CD8(+) T cells by
highly expressed Galectin-3. Clin Invest Med. 2010 Feb 1;33(1):E44-53.

Lin YH, Lin LY, Wu YW, Chien KL, Lee CM, Hsu RB, Chao CL, Wang SS, Hsein YC, Liao LC, Ho YL, Chen MF. The relationship
between serum Galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta. 2009
Nov;409(1-2):96-9.

Mensah-Brown EP, Al Rabesi Z, Shahin A, Al Shamsi M, Arsenijevic N, Hsu DK, Liu FT, Lukic ML. Targeted disruption of the
Galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice. Clin Immunol. 2009
Jan;130(1):83-8.

Miyazaki J, Hokari R, Kato S, Tsuzuki Y, Kawaguchi A, Nagao S, Itoh K, Miura S. Increased expression of Galectin-3 in primary gastric
cancer and the metastatic lymph nodes. Oncol Rep. 2002 Nov-Dec;9(6):1307-12.

Müller S, Schaffer T, Flogerzi B, Fleetwood A, Weimann R, Schoepfer AM, Seibold F. Galectin-3 modulates T cell activity and is
reduced in the inflamed intestinal epithelium in IBD. Inflamm Bowel Dis. 2006 Jul;12(7):588-97.

Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R, Raz A. Inhibition of human cancer cell growth and matastasis in
nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst, 2002; 94:1854-62.

Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A. Galectin-3 induces endothelial cell morphogenesis and
angiogenesis. Am J Pathol. 2000 Mar;156(3):899-909.

Oakley MS, Majam V, Mahajan B, Gerald N, Anantharaman V, Ward JM, Faucette LJ, McCutchan TF, Zheng H, Terabe M, Berzofsky
JA, Aravind L, Kumar S. Pathogenic roles of CD14, Galectin-3, and OX40 during experimental cerebral malaria in mice. PLoS One.
2009 Aug 27;4(8):e6793.

Pienta KJ, Naik H, Akhtar A, Yamazaki K, Replogle TS, Lehr J, Donat TL, Tait L, Hogan V, Raz A. Inhibition of spontaneous matastasis
in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst, March 1, 1995, 1:87(5):348-53.

Platt D, Raz A. Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin. J Natl Cancer Inst, 1994; 84(6):438-42.

Psarras S, Mavroidis M, Sanoudou D, Davos CH, Xanthou G, Varela AE, Panoutsakopoulou V, Capetanaki Y. Regulation of adverse
remodeling by osteopontin in a genetic heart failure model. Eur Heart J. 2011 Apr 26. [Epub ahead of print]
Ramachandran, C, Wilk, BJ, Hotchkiss, A, Chau, H, Eliaz, I. Melnick, SJ. Activation of human T-helper/inducer cell, T-cytotoxic/
suppressor cell, B-cell, and natural killer (NK)-cells and induction of natural killer cell activity against K562 chronic myeloid leukemia
cells with modified citrus pectin. 2011. (Submitted for Publication).

Romanenko AE, Dereviago IB, Litenko VA, Obodovich AN. Further improvement in the administration of pectin as a preventive agent
against absorption of radionuclides by human body. Gig Tr Prof Zabol, 1991;(12):8-10.

Saegusa J, Hsu DK, Chen HY, Yu L, Fermin A, Fung MA, Liu FT. Galectin-3 is critical for the development of the allergic inflammatory
response in a mouse model of atopic dermatitis. Am J Pathol. 2009 Mar;174(3):922-31.

Sethi K, Sarkar S, Das S, Mohanty B, Mandal M. Biomarkers for the diagnosis of thyroid cancer. J Exp Ther Oncol. 2010;8(4):341-52.

Sioud M, Mobergslien A, Boudabous A, Fløisand Y. Evidence for the involvement of Galectin-3 in mesenchymal stem cell suppression
of allogeneic T-cell proliferation. Scand J Immunol. 2010 Apr;71(4):267-74.

Strum,S, Scholz, M, McDermed, J, McCulloch, M, Eliaz, I. Modified citrus pectin slows PSA doubling time: A Pilot Clinical Trial.
International Conference on Diet and Prevention of Cancer. 1999 Tampere, Finland.

Vagnucci Jr AH, Li WW. Alzheimer’s disease and angiogenesis. The Lancet. Feb 15, 2003.

Vankrunkelsven A, De Ceulaer K, Hsu D, Liu FT, De Baetselier P, Stijlemans B. Lack of Galectin-3 alleviates trypanosomiasis-
associated anemia of inflammation. Immunobiology. 2010 Sep-Oct;215(9-10):833-41.

Weiss, T, McCulloch, M, Eliaz, I. Modified citrus pectin induces cytotoxicity of prostate cacner cells in co-cultures with human
endothelial monolayers. International Conference on Diet and Prevention of Cancer. 1999 Tampere, Finland.

Wang CR, Shiau AL, Chen SY, Cheng ZS, Li YT, Lee CH, Yo YT, Lo CW, Lin YS, Juan HY, Chen YL, Wu CL. Intra-articular
lentivirus-mediated delivery of Galectin-3 shRNA and galectin-1 gene ameliorates collagen-induced arthritis. Gene Ther. 2010
Oct;17(10):1225-33.

Wang, Y, Nangia-Makker, P, Larry Tait, T, Vitaly Balan, V, Victor Hogan,V, Kenneth J. Pienta, KJ, Raz, A. Regulation of prostate cancer
progression by Galectin-3. Am J Pathol. 2009 Apr;174(4):1515-23.

Yan, J, and Katz, AE. PectaSol-C modified citrus pectin induces apoptosis and inhibition of proliferation in human and mouse androgen-
dependent and- independent prostate cancer cells. Integr Cancer Ther 2010;9:197-203.

Yu, LJ. Circulating Galectin-3 in the bloodstream: An emerging promoter of cancer metastasis. World J Gastrointest Oncol. 2010 ;
2(4):177-180.

Zhao, Z. Y., Liang, L., Fan, X., Yu, Z., Hotchkiss, A.T., Wilk, B. J., Eliaz, I. The role of modified citrus pectin as an effective chelator of
lead in children hospitalized with toxic lead levels. Altern Ther Health Med. 2008;(4):34-38.

Zhao, Q, Barclay, M, Hilkens, J, Xiuli Guo, X , Barrow, H, Rhodes, JM, Yu, LG. Interaction between circulating Galectin-3 and cancer-
associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Molecular Cancer. 2010, 9:154-166.

Zuberi RI, Hsu DK, Kalayci O, Chen HY, Sheldon HK, Yu L, Apgar JR, Kawakami T, Lilly CM, Liu FT. Critical role for Galectin-3
in airway inflammation and bronchial hyperresponsiveness in a murine model of asthma. Am J Pathol. 2004 Dec;165(6):2045-53.